Mitral valve regurgitation (MR) is a prevalent and often progressive disease affecting more than 4 million Americans. Due to the mitral valve's complex anatomic structure, only a small minority of patients with severe MR have undergone surgical valve repair or replacement. Technical advances now offer patients newer, less invasive options, including MitraClip® and Intrepid™ Transcatheter Mitral Valve Replacement (TMVR). Inova Schar Heart and Vascular’s surgeons and interventional cardiologists, who are among the most experienced in the region, evaluate potential candidates for these procedures.
Patients typically visit the valve clinic once or twice before their scheduled procedure to meet the valve team, including the interventional cardiologist and heart surgeon. They also complete cardiac imaging studies (TEE +/- cardiac CT) during their visits.
Post-procedure, patients return to the valve clinic once or twice for follow up, then return to their primary care provider or local cardiologist for ongoing care.
Intrepid™ Transcatheter Mitral Valve Replacement (TMVR)
Inova offers the Intrepid™ TMVR system, a minimally invasive alternative to open-heart surgical repair for select high surgical risk patients through the Apollo trial. This study evaluates the safety and efficacy of the TMVR System in patients with severe symptomatic mitral regurgitation who are either ineligible or at increased risk for conventional mitral valve surgery.
The MitraClip® procedure is indicated for patients who are not candidates for surgical mitral valve replacement due to prohibitive risk. The device is placed using a minimally invasive catheter-based approach and real-time imaging. Patients generally are discharged home within three days.